Thymalin Dosing Protocol: Thymus Peptide Guide

Herein, we summarize research progression in the field of thymus-mediated immunoendocrine control of cancer, providing insights into how manipulation of the thymic microenvironment can influence treatment outcomes, including clinical responses and adverse effects of therapies. We review data obtained from clinical and preclinical cancer research to evidence the complexity of immunoendocrine interactions underpinning anti-tumor immunity.

Limitations: No placebo control reported. Review article — no new primary data.

We propose that these peptides may form a link between somatic cells and immune as well as neuroendocrine systems. This model may provide a better understanding of the mechanisms underlying immune homeostasis, leading thereby to the development of new therapeutic regimes utilizing the characteristics of thymic peptides.

Limitations: No placebo control reported. Review article — no new primary data.

It is possible that the antiviral effect of thymalin consists in compensatory stimulation of HSC differentiation into CD28+T lymphocytes at the stage of immunity suppression in unfavorable course of viral infection. Thymalin can be considered as an immunoprotective peptide drug for the prevention of COVID-19.

Limitations: No placebo control reported.

Summing up, this article briefly reviews the publications on the physiology of the thymulin-neuroendocrine axis and the anti-inflammatory properties of the molecule and its analog. The availability of novel biotechnological tools should boost basic studies on the molecular biology of thymulin and should also allow an assessment of the potential of gene therapy to restore circulating thymulin levels in thymodeficient animal models and eventually, in humans.

Limitations: No placebo control reported. Review article — no new primary data.

This regulation may be mediated through thymic hormone effects on peripheral immune cell activities and bidirectional coupling between thymic hormones and the hypothalamic-pituitary-adrenal axis. TAKE-HOME MESSAGE: In view of the role of thymic hormones in immune and neuroendocrine systems, they could be suitable as therapeutic agents for inflammation.

Limitations: No placebo control reported. Review article — no new primary data.

We have already shown that Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide first described and characterized by Allan Goldstein in 1972, by modulating signals delivered through innate immune receptors on dendritic cells, affects adaptive immune responses via modulation of Th cell effector and regulatory functions. We will discuss recent molecular mechanisms underlying the ability of Talpha1 to activate or inhibit immune responses.

Limitations: No placebo control reported. Review article — no new primary data.

The enhanced production of neuroendocrine cytokines may affect hormone secretion, neurotransmission, and the development of certain neurodegenerative disorders (e.g., Alzheimer's disease). The isolation of the active component of TF5 that inhibits neuroendocrine and hematopoietic tumor cell proliferation will provide a potential therapeutic strategy for the treatment of these tumors.

Limitations: No placebo control reported. Review article — no new primary data.

These results demonstrate that TP can protect vascular endothelial cells from oxidant injury. The data thus suggest that TP may be useful for the prevention and/or treatment of atherosclerosis, and further suggest that immune modulating agents may directly or indirectly influence the functions of vascular endothelium.

Limitations: Animal study only — human translation uncertain.

On the one hand, the studies demonstrated wide potentialities of the use of thymaline in the treatment of the resistant patterns of schizophrenia. On the other hand, they showed the heterogeneity of immune abnormalities in patients with different varieties of resistance.

Limitations: No placebo control reported.

Finally, no VIP-like immunoreactivity was detected in the thymic peptide extract using an antiserum raised against mammalian VIP. All these data suggest the presence in the bovine thymic peptide extract of a new substance which behaves as a VIP agonist in rat.

Limitations: Animal study only — human translation uncertain.

The effects, in vitro of thymic factors, on peripheral blood lymphocytes isolated from normal donors and patients with primary immunodeficiency disorders, autoimmune disorders, and neoplastic disorders will also be reviewed. Finally, a detailed critical summary of the clinical trials performed with each of the thymic preparations will be presented with an emphasis on treatment of patients with cancer.

Limitations: No placebo control reported. Review article — no new primary data.

A preliminary account is reported of the experiments performed with the aim of raising conventional rabbit antisera to the peptide analogue ACTH 1-17, as well as of the consistently negative results which were obtained when 578 human serum samples (from patients treated with such synthetic peptide) were screened by a radioimmunoassay for the occurrence of anti-ACTH 1-17 antibodies. It is emphasized that the recognition of the rhythmic variations of several immunological mechanisms and of the crucial role played by the analogues of adrenal corticotropic and thymic hormones in immune regulation has favoured significant advances in the fast growing area of chronoimmunology.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported. Review article — no new primary data.